|
|
Volumn 55, Issue 6, 2009, Pages 1300-1301
|
|
Is Metastasectomy for Urothelial Carcinoma Worthwhile?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
DOXORUBICIN;
METHOTREXATE;
VINBLASTINE;
BLADDER CANCER;
BONE METASTASIS;
CANCER COMBINATION CHEMOTHERAPY;
CANCER LOCALIZATION;
CANCER PATIENT;
CANCER SCREENING;
CANCER SURGERY;
CANCER SURVIVAL;
CANCER SURVIVOR;
EDITORIAL;
GERMANY;
HUMAN;
LIVER METASTASIS;
LUNG METASTASIS;
LYMPH NODE METASTASIS;
METASTASECTOMY;
MULTIMODALITY CANCER THERAPY;
OVERALL SURVIVAL;
PARAAORTIC LYMPH NODE;
PATIENT IDENTIFICATION;
PELVIS;
PELVIS LYMPH NODE;
PRIORITY JOURNAL;
SACRUM;
SURVIVAL RATE;
SYSTEMIC THERAPY;
TREATMENT INDICATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
URINARY TRACT CARCINOMA;
VISCERAL METASTASIS;
CARCINOMA, TRANSITIONAL CELL;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
LYMPH NODE EXCISION;
LYMPH NODES;
MALE;
PROGNOSIS;
RISK ASSESSMENT;
SOFT TISSUE NEOPLASMS;
SURVIVAL ANALYSIS;
UROLOGIC NEOPLASMS;
|
|
EID: 65049084351
PISSN: 03022838
EISSN: None
Source Type: Journal
DOI: 10.1016/j.eururo.2008.12.011 Document Type: Editorial |
|
Times cited : (13)
|
|
References (3)
|
